Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 25 | 2023 | 110 | 6.450 |
Why?
|
| Prostate | 13 | 2022 | 32 | 3.640 |
Why?
|
| Kidney Neoplasms | 13 | 2023 | 61 | 2.950 |
Why?
|
| Carcinoma, Renal Cell | 9 | 2023 | 36 | 2.070 |
Why?
|
| Image-Guided Biopsy | 11 | 2022 | 26 | 1.760 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2022 | 1247 | 1.440 |
Why?
|
| Robotic Surgical Procedures | 4 | 2023 | 18 | 1.250 |
Why?
|
| Robotics | 3 | 2023 | 10 | 1.140 |
Why?
|
| Nephrectomy | 8 | 2017 | 29 | 0.960 |
Why?
|
| Nomograms | 1 | 2021 | 5 | 0.800 |
Why?
|
| Germ-Line Mutation | 3 | 2016 | 9 | 0.790 |
Why?
|
| Male | 43 | 2023 | 15850 | 0.740 |
Why?
|
| Humans | 52 | 2023 | 29811 | 0.650 |
Why?
|
| Waiting Lists | 1 | 2017 | 15 | 0.600 |
Why?
|
| Kidney Transplantation | 3 | 2017 | 126 | 0.590 |
Why?
|
| Renal Dialysis | 1 | 2017 | 110 | 0.560 |
Why?
|
| Retrospective Studies | 13 | 2023 | 3325 | 0.550 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 3 | 0.550 |
Why?
|
| Ultrasonography, Interventional | 6 | 2020 | 63 | 0.530 |
Why?
|
| Heterozygote | 1 | 2016 | 103 | 0.520 |
Why?
|
| Prostate-Specific Antigen | 7 | 2022 | 16 | 0.520 |
Why?
|
| Laparoscopy | 4 | 2023 | 143 | 0.490 |
Why?
|
| Ultrasonography | 6 | 2019 | 224 | 0.480 |
Why?
|
| Biopsy | 6 | 2022 | 239 | 0.470 |
Why?
|
| Middle Aged | 28 | 2022 | 9960 | 0.450 |
Why?
|
| Aged | 21 | 2022 | 9620 | 0.440 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 5 | 2020 | 8 | 0.410 |
Why?
|
| Perineum | 2 | 2021 | 5 | 0.400 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2017 | 26 | 0.400 |
Why?
|
| Biopsy, Large-Core Needle | 3 | 2021 | 7 | 0.350 |
Why?
|
| Kidney Diseases | 2 | 2012 | 117 | 0.350 |
Why?
|
| Prostatic Hyperplasia | 3 | 2013 | 12 | 0.330 |
Why?
|
| Ureter | 2 | 2023 | 15 | 0.310 |
Why?
|
| Multimodal Imaging | 3 | 2017 | 20 | 0.280 |
Why?
|
| Prospective Studies | 6 | 2023 | 1823 | 0.270 |
Why?
|
| Urinary Tract Infections | 1 | 2006 | 32 | 0.270 |
Why?
|
| Kidney | 3 | 2023 | 176 | 0.270 |
Why?
|
| Adult | 14 | 2017 | 8741 | 0.230 |
Why?
|
| Ureteral Obstruction | 1 | 2023 | 11 | 0.230 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 4930 | 0.220 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 379 | 0.220 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2022 | 1 | 0.210 |
Why?
|
| Cystectomy | 2 | 2019 | 4 | 0.200 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2021 | 37 | 0.200 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 4 | 0.200 |
Why?
|
| Prostatectomy | 2 | 2023 | 21 | 0.190 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2004 | 19 | 0.180 |
Why?
|
| Urinary Bladder | 1 | 2019 | 20 | 0.170 |
Why?
|
| Urology | 1 | 2019 | 16 | 0.170 |
Why?
|
| Predictive Value of Tests | 7 | 2014 | 532 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2019 | 36 | 0.170 |
Why?
|
| Survival Rate | 2 | 2017 | 376 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 401 | 0.160 |
Why?
|
| Ablation Techniques | 1 | 2017 | 3 | 0.150 |
Why?
|
| United States | 4 | 2017 | 2344 | 0.150 |
Why?
|
| Female | 14 | 2017 | 16410 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2017 | 23 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 33 | 0.150 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 57 | 0.150 |
Why?
|
| Phototherapy | 1 | 2017 | 37 | 0.150 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2017 | 3 | 0.150 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 20 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2017 | 66 | 0.140 |
Why?
|
| ErbB Receptors | 1 | 2017 | 73 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 44 | 0.140 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 6 | 0.130 |
Why?
|
| Registries | 1 | 2017 | 191 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 3 | 2004 | 14 | 0.130 |
Why?
|
| Succinate Dehydrogenase | 1 | 2015 | 3 | 0.130 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2015 | 2 | 0.130 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2015 | 3 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 158 | 0.120 |
Why?
|
| Disease Management | 2 | 2016 | 122 | 0.120 |
Why?
|
| Neoplasm Grading | 4 | 2018 | 53 | 0.120 |
Why?
|
| Kallikreins | 1 | 2014 | 2 | 0.120 |
Why?
|
| Prognosis | 5 | 2017 | 874 | 0.120 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2013 | 3 | 0.120 |
Why?
|
| SEER Program | 4 | 2015 | 38 | 0.120 |
Why?
|
| Animals | 5 | 2017 | 4637 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2013 | 62 | 0.110 |
Why?
|
| Urothelium | 1 | 2013 | 5 | 0.110 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 4 | 0.110 |
Why?
|
| Estrogens | 1 | 2013 | 37 | 0.110 |
Why?
|
| Time Factors | 1 | 2017 | 1641 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2002 | 19 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 332 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 90 | 0.100 |
Why?
|
| Fungal Proteins | 1 | 2011 | 7 | 0.100 |
Why?
|
| Threonine | 1 | 2011 | 7 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 7 | 0.100 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 13 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 1859 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2023 | 3561 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2016 | 310 | 0.090 |
Why?
|
| Watchful Waiting | 2 | 2022 | 9 | 0.080 |
Why?
|
| Nitriles | 2 | 2022 | 13 | 0.080 |
Why?
|
| Young Adult | 4 | 2015 | 1966 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 273 | 0.070 |
Why?
|
| Malacoplakia | 1 | 2006 | 1 | 0.070 |
Why?
|
| Pyelonephritis | 1 | 2006 | 1 | 0.070 |
Why?
|
| Tuberculosis, Renal | 1 | 2006 | 1 | 0.070 |
Why?
|
| Adolescent | 4 | 2015 | 2332 | 0.070 |
Why?
|
| Emphysema | 1 | 2006 | 4 | 0.070 |
Why?
|
| Abscess | 1 | 2006 | 26 | 0.070 |
Why?
|
| Risk Factors | 3 | 2022 | 2465 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 399 | 0.060 |
Why?
|
| Depsipeptides | 1 | 2004 | 1 | 0.060 |
Why?
|
| Burkitt Lymphoma | 1 | 2004 | 7 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2004 | 9 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 13 | 0.060 |
Why?
|
| Child | 3 | 2015 | 1377 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2004 | 13 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 147 | 0.060 |
Why?
|
| Urologic Surgical Procedures | 1 | 2023 | 7 | 0.060 |
Why?
|
| Kidney Pelvis | 1 | 2023 | 9 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2014 | 1952 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 10 | 0.060 |
Why?
|
| Organ Size | 2 | 2013 | 107 | 0.050 |
Why?
|
| Incidence | 2 | 2017 | 759 | 0.050 |
Why?
|
| Phenylthiohydantoin | 1 | 2022 | 1 | 0.050 |
Why?
|
| Benzamides | 1 | 2022 | 18 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 56 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2017 | 683 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 252 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2013 | 102 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 25 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 134 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2001 | 22 | 0.050 |
Why?
|
| Androgens | 1 | 2021 | 8 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2021 | 4 | 0.050 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 5 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2001 | 68 | 0.050 |
Why?
|
| Patient Selection | 2 | 2013 | 234 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 174 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 364 | 0.050 |
Why?
|
| Mice | 3 | 2017 | 1628 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 558 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 802 | 0.040 |
Why?
|
| Education | 1 | 2019 | 40 | 0.040 |
Why?
|
| Simulation Training | 1 | 2019 | 34 | 0.040 |
Why?
|
| HIV Infections | 1 | 2006 | 997 | 0.040 |
Why?
|
| Infrared Rays | 1 | 2017 | 1 | 0.040 |
Why?
|
| Photosensitizing Agents | 1 | 2017 | 5 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2017 | 10 | 0.040 |
Why?
|
| Seminal Vesicles | 1 | 2015 | 4 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 270 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2002 | 957 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 33 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 95 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 86 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 4 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 291 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2014 | 57 | 0.030 |
Why?
|
| Heredity | 1 | 2013 | 6 | 0.030 |
Why?
|
| Dutasteride | 1 | 2013 | 2 | 0.030 |
Why?
|
| Azasteroids | 1 | 2013 | 2 | 0.030 |
Why?
|
| Finasteride | 1 | 2013 | 2 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 331 | 0.030 |
Why?
|
| Pedigree | 1 | 2013 | 65 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2013 | 26 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2013 | 29 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 20 | 0.030 |
Why?
|
| Age of Onset | 1 | 2013 | 108 | 0.030 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2013 | 3 | 0.030 |
Why?
|
| Contrast Media | 1 | 2014 | 125 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 2 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 32 | 0.030 |
Why?
|
| Propionates | 1 | 2013 | 13 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2004 | 20 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 28 | 0.030 |
Why?
|
| Michigan | 1 | 2013 | 15 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 18 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2013 | 30 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 87 | 0.030 |
Why?
|
| Nephrons | 1 | 2012 | 6 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 222 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 81 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 191 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 362 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 80 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2013 | 206 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2012 | 24 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 78 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 200 | 0.020 |
Why?
|
| Solvents | 1 | 2011 | 5 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 52 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 432 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 504 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 349 | 0.020 |
Why?
|
| Chaperonins | 1 | 2011 | 1 | 0.020 |
Why?
|
| Casein Kinase II | 1 | 2011 | 2 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 812 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2011 | 10 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 19 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 132 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2011 | 18 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 31 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 16 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 63 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 159 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 491 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 866 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 853 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2004 | 744 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 969 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 411 | 0.020 |
Why?
|
| Thymidine | 1 | 2004 | 7 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2004 | 5 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2004 | 4 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 30 | 0.020 |
Why?
|
| Cell Division | 1 | 2004 | 112 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2004 | 45 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2004 | 202 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2004 | 110 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 2003 | 2 | 0.010 |
Why?
|
| Zidovudine | 1 | 2003 | 40 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 259 | 0.010 |
Why?
|
| Ganciclovir | 1 | 2003 | 27 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 173 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 324 | 0.010 |
Why?
|
| Leukocyte Transfusion | 1 | 2001 | 2 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2001 | 57 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2003 | 136 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 279 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 63 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2001 | 88 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2001 | 93 | 0.010 |
Why?
|
| Rats | 1 | 2003 | 876 | 0.010 |
Why?
|